TGTX Share Price Performance
US$31.13
0.06 (0.21%)
29.7% undervalued intrinsic discount
US$44.29
Fair Value
Price US$31.13
AnalystConsensusTarget US$44.29
AnalystLowTarget US$11.00
AnalystHighTarget US$53.00
Fair ValueUS$44.29
Share Pricen/a
TG Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 111 Fair Values set on narratives written by author
TGTX Community Narratives
AN
Fair Value US$44.29 29.7% undervalued intrinsic discount
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
0users have liked this narrative
0users have commented on this narrative
60users have followed this narrative
AN
Fair Value US$12.34 152.3% overvalued intrinsic discount
Pricing Pressures And Competitive Risks Will Impair Market Strength
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$53 41.3% undervalued intrinsic discount
Aging Populations And Self-Administration Will Transform MS Care
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
Key Takeaways The upcoming launch of subcutaneous BRIUMVI and expanded market access are set to drive substantial long-term revenue and sales growth. Strong commercial execution, demographic trends, and a lean operational model create pathways for ongoing market penetration and margin improvement.Read more
912
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
60users have followed this narrative
AN
US$44.29
29.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
37.82% p.a.
Profit Margin
32.93%
Future PE
17.69x
Price in 2028
US$54.37
Pricing Pressures And Competitive Risks Will Impair Market Strength
Key Takeaways Dependence on BRIUMVI exposes the company to competitive pressures, regulatory risks, and potential loss of pricing power, threatening revenue growth and market share. Rising operational costs and looming patent expiration increase margin pressure and vulnerability to revenue decline as generic and biosimilar competition intensifies.Read more
31
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$12.34
152.3% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
31.54% p.a.
Profit Margin
33.35%
Future PE
6.67x
Price in 2028
US$15
Aging Populations And Self-Administration Will Transform MS Care
Key Takeaways Accelerated adoption of BRIUMVI and its subcutaneous formulation could rapidly boost market share, revenues, and persistency due to payer and consumer preference trends. Strong clinical pipeline, brand momentum, and demographic tailwinds position the company for superior long-term growth and margin expansion compared to competitors.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$53
41.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
48.17% p.a.
Profit Margin
44.29%
Future PE
15.09x
Price in 2028
US$64.41
Trending Discussion
Recently Updated Narratives
AN
TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches
Fair Value: US$44.29 29.7% undervalued intrinsic discount
60 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pricing Pressures And Competitive Risks Will Impair Market Strength
Fair Value: US$12.34 152.3% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Self-Administration Will Transform MS Care
Fair Value: US$53 41.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
TG Therapeutics, Inc. Key Details
About TGTX
- Founded
- 1993
- Employees
- 374
- CEO
- WebsiteView website
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
